FDA 483 - Peoples Pharmacy, Inc. - December 07, 2017

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection revealed four key deficiencies related to the facility's quality system and manufacturing operations.

Firstly, the firm failed to establish adequate procedures for the cleaning and maintenance of equipment, which is critical for preventing contamination and ensuring product quality. Secondly, the manufacturing process for Drug X was not adequately validated. This indicates a lack of scientific evidence demonstrating that the process consistently produces a product meeting its predetermined specifications and quality attributes. Thirdly, the firm did not maintain proper records of batch production and control, which is a fundamental requirement for traceability, quality assurance, and regulatory compliance. Lastly, the firm did not conduct adequate training for employees in current Good Manufacturing Practice (cGMP) requirements, suggesting a potential lack of understanding or adherence to regulatory standards among personnel. These observations collectively point to significant issues in the facility's quality management system, potentially impacting the safety, efficacy, and quality of the drug products manufactured.